Lv5
870 积分 2024-11-29 加入
Dual Inhibitors of KRASG12D and HSP90 Are Effective against KRASG12D Inhibitor Resistance
3小时前
待确认
Discovery and Characterization of RP03707: A Highly Potent and Selective KRAS G12D PROTAC
3小时前
待确认
Discovery and Characterization of RP04340: A Highly Potent and Orally Active Pan-KRAS PROTAC Degrader
5小时前
待确认
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
5天前
已完结
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
1个月前
已完结
KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial
1个月前
已完结
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
2个月前
已完结
Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond
2个月前
已完结
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer
2个月前
已完结
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
